Astellas Taps Proteostasis In Potential $1.2bn Alliance
This article was originally published in PharmAsia News
Assuming all milestones are met and options exercised, a new deal with Japan's Astellas will provide a bonanza for Proteostasis, being worth potentially more than $1.2 billion to the privately held U.S. drug discovery venture.
You may also be interested in...
Cleave Biosciences leads off a recent slate of venture capital financings with $37m to fund ongoing Phase I programs for the lead drug from its protein homeostasis-focused platform.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.